Nucleic acid detection techniques for adventitious agent testing by Brien, Kaitlin Elizabeth
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2015
Nucleic acid detection techniques for adventitious
agent testing
Kaitlin Elizabeth Brien
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Genetics Commons, and the Virology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Brien, Kaitlin Elizabeth, "Nucleic acid detection techniques for adventitious agent testing" (2015). Graduate Theses and Dissertations.
14322.
https://lib.dr.iastate.edu/etd/14322
  
 
 
Nucleic acid detection techniques for adventitious agent testing 
 
 
by 
 
 
Kaitlin Elizabeth Brien  
 
 
 
A thesis submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
 
 
Co-Majors: Microbiology, Genetics  
 
Program of Study Committee: 
Joseph Hermann, Co-Major Professor  
Cathy Miller, Co-Major Professor 
Karin Dorman 
Bradley Blitvich 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2015 
 
 
 
Copyright © Kaitlin Elizabeth Brien, 2015. All rights reserved.
ii 
 
TABLE OF CONTENTS 
              Page 
LIST OF FIGURES ....................................................................................................  iii 
LIST OF TABLES ......................................................................................................  iv 
ACKNOWLEDGMENTS ..........................................................................................  v 
ABSTRACT………………………………................................................................  vi 
CHAPTER 1. GENERAL INTRODUCTION ........................................................  1 
 Introduction  ............................................................................................................        1 
 Thesis Organization  ...............................................................................................        2 
 Literature Review ................................................................................................ 3 
  
CHAPTER 2. EVALUATION OF A VIRAL MICROARRAY AND NEXT-
GENERATION SEQUENCING FOR DETECTION OF ADVENTITIOUS  
AGENTS IN VETERINARY VACCINES ..............................................................      21 
 Abstract  ..............................................................................................................    21 
 Introduction  ............................................................................................................  22 
 Materials and Methods  ...........................................................................................  23 
 Results  ................................................................................................................ 27 
 Discussion  ..........................................................................................................  29 
 Acknowledgments ............................................................................................. .  34 
 References ........................................................................................................... 34 
 
CHAPTER 3. EVALUATION OF A VIRAL MICROARRAY AND NEXT- 
GENERATION SEQUENCING FOR DETECTION OF BOVINE VIRAL  
DIARRHEA VIRUSES ..........................................................................................  44 
 Abstract ...............................................................................................................  44 
 Introduction ......................................................................................................... 44 
 Materials and Methods ........................................................................................ 46 
 Results ................................................................................................................. 46 
 Discussion ...........................................................................................................  48 
 References ........................................................................................................... 49 
 
CHAPTER 4. GENERAL CONCLUSIONS ........................................................ 52 
 
 
iii 
 
LIST OF FIGURES  
 
                                                                                                                                       Page 
 
Figure 1 Sample preparation workflow followed to amplify viral RNA/DNA  
       prior to microarray or sequencing ..........................................................  38 
 
Figure 2  NGS data analysis workflow followed starting with raw FASTQ files  
       from the sequencing instrument..............................................................  39 
 
 
iv 
 
LIST OF TABLES 
                                                                                                                                  Page 
Table 1 Mock contaminants selected represent diverse viral families and genome  
       types ..........................................................................................................  37 
 
Table 2    Vaccines selected represent diverse viral families and genome types ....... 37 
 
Table 3 Mock contaminants tested independently by microarray and sequencing  40 
Table 4 Licensed vaccines tested independently by microarray and sequencing ... 41 
Table 5 Avian mock contaminant and vaccine combinations tested by microarray  
       and sequencing ...................................................................................... 42 
 
Table 6 Mammalian mock-contaminant and vaccine combinations tested by  
       microarray and sequencing .................................................................... 43 
 
Table 7   Cross-detection of bovine viral diarrhea virus 1 (BVDV-1) and bovine  
       viral diarrhea virus 2 (BVDV-2) in samples in which only one virus is 
       present ................................................................................................... 51 
 
Table 8  Detection of BVDV-1 and BVDV-2 viruses in a sample in which both  
       viruses are present. ..................................................................................  51 
 
Table 9 Detection of two strains of BVDV-1 in a sample in which both strains  
       are present .................. ............................................................................  51 
 
v 
 
ACKNOWLEDGMENTS 
 
I would like to thank my committee chairs, Dr. Joseph Hermann and Dr. Cathy 
Miller, and my committee members, Dr. Karin Dorman and Dr. Bradley Blitvich, for their 
guidance and support throughout the course of this research. Thanks also to several 
wonderful individuals who without their scientific expertise and mentorship this project 
would not have been possible: Dr. Roger Barrette, Tod Stuber, Alethea Fry, Alexa Scupham, 
and Patrick Camp. 
In addition, I would like to thank the USDA for the Veterinary Services Daniel E. 
Salmon Scholarship, which provided financial support over the course of my Master’s 
program. I would also like to thank my friends and colleagues at the USDA and the faculty 
and staff in the Iowa State University Interdepartmental Microbiology and Genetics 
programs for making my time at Iowa State University a wonderful experience. Finally, 
thanks to my family and friends for their encouragement. 
 
 
vi 
 
ABSTRACT  
 
The availability of safe and effective animal vaccines is critical for the prevention of 
animal disease. Adventitious agent testing is done on master seed viruses prior to vaccine 
licensure to ensure that no biological contaminants were introduced during manufacture. 
Traditional adventitious agent testing is performed using a variety of cell culture lines and a 
panel of polymerase chain reaction tests. The purpose of this research was to determine if 
new technologies like DNA microarray and next-generation sequencing (NGS) could be of 
any benefit for adventitious agent testing. A literature review describes the state of the field 
and the challenges that will have to be addressed to use these technologies in a regulatory 
environment. Both techniques were tested on a panel of mammalian and avian viruses, and 
each virus was tested individually and in combination with other viruses. NGS was found to 
be a more reliable method of screening for adventitious agents than microarray.  
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
The Center for Veterinary Biologics is responsible for ensuring that pure, safe, 
potent, and effective biologics are available for the diagnosis, treatment, and prevention 
of animal diseases. Prior to licensure of a new vaccine, manufacturers must submit a 
sample of their master seed virus, which will be used as the source material to produce 
the vaccine. Master seed viruses are tested for adventitious agents to ensure that no 
biological contaminants were inadvertently introduced. Primary methods of adventitious 
agent testing for viruses include cell culture testing conducted according to the 9 Code of 
Federal Regulations and polymerase chain reaction (PCR) tests [1]. However, cell culture 
detection is lengthy, labor intensive, and relies on the availability of a permissive cell 
line. PCR tests can only be performed for a selected number of agents. If a potential 
adventitious agent is not cell-culture adapted or is not targeted by a PCR, it may not be 
detected. Recent technologies based on the broad detection of viral nucleic acids, like 
microarray and next-generation sequencing (NGS), could be used to increase the range of 
detectable viruses in adventitious agent testing.  
Microarray and NGS have been successfully used to detect unknown pathogens in 
diagnostic laboratories [2-6] . However, diagnostic samples are often the result of an 
acute infection with high levels of a single pathogen. Adventitious agent testing requires 
the detection of both the vaccine virus and any adventitious viruses, with the adventitious 
viruses potentially present at much lower concentrations. Additional work is needed to 
determine if these technologies could be suitable screening tools for adventitious agents. 
Many recent studies focus on recovery of a single virus at a time and determining a limit 
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of detection [7-12]. While it is critical to have an estimate of sensitivity for new methods, 
determining whether multiple viruses can be detected in combination is equally critical. 
To determine whether microarray and NGS can reliably detect multiple viruses in a 
sample, a novel DNA microarray and Illumina sequencing were used to detect a panel of 
mammalian and avian viruses. All viruses were tested both individually and in 
combinations. In most cases, each method was able to detect both viruses, although both 
methods had failures. NGS had a higher detection rate than the microarray. Furthermore, 
NGS provides higher confidence in the results because it is able to provide more 
information than microarray, like the specific strain of virus detected, percent genome 
coverage, and average depth of sequencing.  
Additional work is needed to determine the reliability and sensitivity of NGS 
before it can be used to confidently rule out the presence of adventitious agents in master 
seeds. However, these preliminary results show that this novel microarray and NGS can 
be used in conjunction with traditional methods for adventitious agent testing. 
Thesis Organization 
 This thesis is organized into four chapters. Chapter one provides a general 
introduction to the rationale guiding this research. The literature review following the 
general introduction describes the challenges facing this area of research and details the 
accomplishments of other laboratories to date. Chapter two details the work I have done 
to answer the question of whether microarray and NGS would be suitable for use in 
adventitious agent testing. Chapter three provides an example of using microarray and 
NGS to detect bovine viral diarrhea virus, a common adventitious agent. Figures in 
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chapter two and three can be found following the acknowledgments and references at the 
end of each chapter. Chapter four contains general conclusions of this research. 
Literature Review 
Introduction 
 Animal vaccination has greatly improved the health of humans and animals since 
the 1800s when Edward Jenner’s smallpox vaccine was introduced [13]. Vaccination has 
been the driving force for the global eradication of rinderpest and the elimination of foot-
and-mouth disease from Europe [14]. However, the reasons for veterinary vaccination go 
beyond animal health and welfare. Human health is protected from zoonotic agents like 
rabies [15]. Veterinary vaccination also promotes sustainable livestock production by 
preventing the use of mass slaughter in response to a disease outbreak [16].   
 The many benefits of vaccination, however, are dependent on the availability of 
safe and effective vaccines. Vaccines, whether killed, modified-live, or recombinant, are 
all vulnerable to contamination by biological organisms throughout the course of 
manufacturing [17]. These contaminating biological organisms are referred to as 
adventitious agents, and the World Health Organization (WHO) describes them as 
“contaminating microorganisms of cell culture or source materials ... that have been 
unintentionally introduced into the manufacturing process of a biological product” [18].  
Contaminants can be introduced through source material including cell substrates and 
serum that may contain endogenous viruses. In addition, cross-contamination by 
infectious materials from the laboratory or equipment can introduce contaminants to the 
vaccine [17].  
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Current testing for adventitious viruses 
 Whatever the source of contamination, both vaccine manufacturers and regulators 
have a vested interest in ensuring that vaccines are free of adventitious agents. Testing for 
adventitious agents in master seed viruses is governed by the 9 Code of Federal 
Regulations [1]. Master seed viruses are the pure viral stocks that will be propagated to 
produce a vaccine. After a master seed virus is approved, a vaccine will not be tested 
again for adventitious agents because the finished product is often composed of several 
viruses and adjuvants that can complicate testing.  
 Requirements for master seed testing are determined by the species of the vaccine 
recipient as well as the animal origin of any products that were used during production. 
For example, if a poultry vaccine is produced in eggs, but fetal bovine serum was used at 
any point in production, it would have to undergo testing for poultry and bovine 
adventitious agents. Testing for specific viruses is done using detection techniques 
including fluorescent antibody staining and polymerase chain reaction (PCR). All 
mammalian master seed viruses are tested for rabies virus, reovirus, and bovine viral 
diarrhea virus. Testing for nonspecific adventitious viruses is done by inoculating the 
neutralized master seed virus into cell culture or eggs and observing the cells or eggs for 
signs of infection after several passages [19].  
 Although the scope of adventitious agent testing is fairly broad, it is well 
recognized that there are instances when it has failed to detect an adventitious virus. 
Cases from the human literature include the detection of SV40 virus in poliomyelitis 
virus vaccines and the detection of avian leukosis virus in yellow fever and measles 
vaccines [20, 21]. More recently, porcine circovirus-1 was detected in a rotavirus vaccine 
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[22]. Veterinary vaccines have also been found to be contaminated. Reticuloendotheliosis 
virus and Newcastle disease virus have been detected in live poultry vaccines [23, 24]. 
Bluetongue virus was found in a canine vaccine, causing abortions and deaths in pregnant 
bitches [25]. A bovine viral diarrhea virus (BVDV) vaccine strain transmission study was 
disrupted by a vaccine recall caused by the presence of an additional strain of BVDV in 
the vaccine [26]. As others have pointed out, the detection of adventitious agents in 
biologicals is rare due to good manufacturing practices, including testing of raw materials 
and substrates [27, 28]. However, the potential consequences of an adventitious virus 
being present in a vaccine warrant a high degree of caution.  
 In addition to these documented cases of adventitious agents slipping through the 
regulatory process, there are several general problems with the current testing 
methodology. Cell culture testing for adventitious viruses takes a minimum of three 
weeks to complete, and it is common to have to repeat testing due to difficulty 
neutralizing the master seed virus. If there were to be a disease outbreak and a vaccine 
needed to be licensed quickly, it would not be ideal for the master seed virus to have to 
go through several weeks of testing. In addition, it is possible that a replication-
competent adventitious virus would not be able to grow in the cell cultures that are used 
for testing. Nucleic acid detection techniques like PCR are more able to detect virus in 
this situation, but due to practical constraints, PCR tests can only be conducted for a 
limited number of viruses. Therefore, there is a chance that traditional adventitious agent 
testing would miss a novel or unexpected virus. A virus detected by nonspecific testing 
techniques may take weeks to identify. These cases of contamination and general 
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disadvantages highlight the shortcomings of current methods of adventitious agent 
testing. 
Alternative broad-spectrum strategies to detect adventitious viruses: microarray 
and next-generation sequencing  
 
 Microarray and next-generation sequencing (NGS) may be able to address some 
of the limitations of traditional adventitious agent testing. Results can be obtained in a 
few days, as opposed to weeks for cell culture testing. Both of these techniques, like 
PCR, are based on detection of viral nucleic acids to signify the presence of viral 
particles. The difference between these techniques and PCR, however, is that these 
techniques are broad-spectrum, meaning they can simultaneously detect a multitude of 
viruses. No prior knowledge about the sample is required for testing because the viral 
nucleic acid is amplified using random primers. This random primer based approach to 
amplification could almost certainly expand the range of viruses detected, as well as 
decreasing the time to results. 
 One specific case highlights the benefits of using random priming to screen for all 
viral nucleic acids. In 2004, a novel pestivirus, ‘D32/00_HoBi’, was isolated from fetal 
bovine serum (FBS) originating from Brazil [29]. The virus is extremely different from 
other pestiviruses in terms of both genome sequence and antigenic properties. These 
differences prompted Schirrmeier et al. to propose that the virus belongs to a new 
pestivirus species, bovine viral diarrhea virus 3 (BVDV-3) [29]. Another BVDV-3 isolate 
was discovered in Switzerland during routine screening of FBS [30]. The FBS was 
negative for BVD by virus isolation and ELISA, but the BVD PCR detected virus. In 
neither instance were the conventional 324/326 primers used, and further investigation 
determined these primers are incapable of HoBi virus amplification [30, 31]. Had the 
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laboratories had been using the conventional primers, the variant virus might not have 
been detected. Random primer amplification followed by microarray or NGS could have 
detected the variant viruses because sequence differences between the virus and the 
primer pairs would not impede amplification.  
  Although broad-spectrum nucleic acid detection could improve the range of 
detectable viruses by using random priming amplification, it may also complicate follow-
up analysis. If viral nucleic acid is detected by microarray or NGS, the sample would 
have to undergo further testing to determine if replication-competent viral particles are 
present in the sample, or if not, whether any risk is incurred by the presence of viral 
nucleic acid. Many commonly used cell substrates for vaccine production contain 
endogenous viruses (usually retroviruses) or latent DNA viruses, which would be a 
source for viral nucleic acids in master seed stocks. For example, the feline endogenous 
retrovirus RD-114 was detected in canine vaccines [32]. All seed stocks contained RNA 
from the virus, but only 7/18 had infectious particles. Species-specific pathogenicity of 
any viruses found must also be considered. RD-114 is nonpathogenic in cats, but it can 
replicate in canine cell culture and therefore could potentially cause disease in dogs. Risk 
analyses will have to be carefully conducted for any viruses identified by microarray or 
NGS [33].  
 The benefits and concerns of using microarray and NGS are shared between both 
technologies, but they also have significant differences. One difference is in the timing of 
bioinformatics analysis. The bioinformatics analysis is done up-front to design a 
microarray. Microarray features are designed based on conserved regions of the genomes 
of interest, which are obtained from databases [34]. In contrast, all analysis on NGS data 
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is done after sequencing has been completed. Time to complete the test is another 
difference. It takes less time to complete a microarray test than NGS. Sensitivity and off-
target tolerance is another difference between microarray and NGS [35]. PCR is a good 
example of a technology with very high sensitivity and low off-target tolerance. The 
sensitivity is high because minute quantities of DNA can be detected using PCR, but the 
off-target tolerance is low because small changes to the genome sequence in the primer-
binding region may inhibit detection. On the other hand, NGS has low sensitivity and 
high off-target tolerance. The sensitivity is low because most of the reads (without any 
viral enrichment) will be eukaryotic or bacterial, which can adversely affect virus 
detection. The off-target tolerance is high because there is no targeting of detection with 
the use of primers. Microarrays fall in the middle. They have a higher off-target tolerance 
than PCR because they have features designed to target multiple points of many viruses. 
The sensitivity is lower than PCR, though, because of higher background fluorescence in 
the assay [35].  
 In addition to these differences, the type of data produced and method of analysis 
is different between the two technologies. Microarray produces a spreadsheet in which 
each feature’s fluorescence is quantified. Microarray data is analyzed by clustering the 
positive features into groups that correspond to viruses. The end result is a list of possible 
viruses with the percentage of positive features for each virus. It is also possible to do 
statistical analysis by predicting virus-specific hybridization profiles to determine 
whether those percentages are higher than chance [36]. The specificity of identification is 
unique to each microarray, but typically it is less specific than NGS. NGS produces a 
very large text file with millions of 250 base pair DNA sequences. NGS data analysis 
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relies on matching the 250 base pair reads against a database of virus genome sequences. 
The results are the number of reads that align to a specific virus genome, the percentage 
of the genome that is covered by the reads, and the average depth of sequencing.  
Review of previous research  
 Several previous studies have investigated the possibility of using microarray and 
NGS for adventitious agent testing. The most notable effort in the microarray arena has 
been the group from Lawrence Livermore National Laboratory with the development of 
their microbial detection array (MDA) [36, 37]. They surveyed seven publicly available 
vaccines for adventitious agents using the MDA and discovered that one of the rotavirus 
vaccines they tested was contaminated with porcine circovirus-1 [22]. The results were 
confirmed with NGS. The MDA was also used in a study to determine sensitivity of 
detection compared to quantitative PCR (qPCR) for five viruses [8]. It was concluded 
that the MDA has sensitivity rivaling qPCR if the background nucleic acids are reduced. 
In addition, it was determined that hybridization time can be reduced to as little as one 
hour, although with a small decrease in sensitivity [38]. 
 Testing cell substrates for adventitious agents is another important application of 
NGS. The Food and Drug Administration (FDA) Center for Biologics Evaluation and 
Research has done research into using NGS to detect viruses in cell substrates [39]. They 
tested six cell lines known to express viral genes or particles using both 454 and Illumina 
sequencing. Prior to sequencing, the samples were amplified and sequencing adapters 
were added with degenerate oligonucleotide-primed PCR. This amplification strategy 
combined with viral enrichment and Illumina sequencing was found to be the most 
sensitive method. Additionally, a novel rhabdovirus in the Sf9 insect cell line was 
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discovered using the same amplification protocol and NGS [40]. Chinese hamster ovary 
cells have been involved in multiple bioreactor contaminations, and one manufacturer, 
Genzyme, was able to use NGS without amplification of the nucleic acid to determine the 
identity of the contaminant [10, 41]. In addition, they performed spike recovery 
experiments with six bacteriophage or viral vectors. The sensitivity with their method 
was quite high, less than one copy per cell for each sample, although their threshold for 
detection was set fairly low at twenty reads. 
 In addition to using NGS to screen cell substrates for viruses, a variety of 
experiments have been performed by several other researchers. Cabannes et al. have 
proposed a method to use different filtration and nucleic acid extraction protocols prior to 
NGS to determine if viral particles, viral genomes, or both, are present in a sample [9]. 
David Onions and John Kohlman developed a degenerate oligonucleotide-primed PCR 
amplification protocol for 454 sequencing with which they discovered a novel bovine 
parvovirus in bovine serum [42]. Gagnieur et al. sequenced several batches of bovine 
serum and trypsin using NGS in order to catalog the diversity found there [43]. Ng et al. 
used human cytomegalovirus as a model virus to compare detection by conventional cell 
culture methods, qPCR, and NGS [44]. These studies are only a small representation of 
the ways NGS is being studied for virus detection in biologics and in clinical samples.  
 The experiments detailed above are certainly valuable, but for technologies like 
microarray and NGS to gain traction in the global biologics regulatory arena, a 
coordinated effort by the regulatory community and industry must occur. This was the 
topic of the workshop “Advanced Technologies for Virus Detection in the Evaluation of 
Biologicals- Applications and Challenges” held in 2013 by the Parenteral Drug 
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Association (PDA) and the FDA [45]. One of the studies presented there by Modrof et al. 
attempts to address the problem of how to evaluate and standardize methods used by 
different researchers [7]. Four blinded samples, spiked at different concentrations into 
different media, were sent to four laboratories, which either used microarray, PCR-
electrospray ionization mass spectrometry, or NGS to identify the samples. The majority 
of the samples were identified correctly regardless of technology (83% of the time), but 
false-positives were frequently reported (31% of the time). More of these types of studies 
will have to be coordinated as the field moves towards developing best practices for these 
methods. Currently only the human vaccine industry and regulators are involved in this 
working group, but it would be advantageous to include veterinary regulators in the 
interest of the One Health Initiative [46].  
Computational considerations for implementing microarray or NGS for 
adventitious agent testing 
 
 The analysis of microarray and NGS data requires a much larger reliance on 
computational resources than typical laboratory techniques. A basic microarray analysis 
involves calculating the mean and standard deviation of the thousands of microarray 
features. The positive features are clustered into groups based on which viral genus or 
species each feature was designed to detect. More complicated algorithms exist to assign 
probability to the results [36, 47, 48]. They require determining predicted hybridization 
profiles for each virus that is represented on the array. Then, the actual hybridization 
profile is compared to the predicted one to determine a probability that the virus is 
present in the sample. These types of analyses are specific to each microarray design. For 
microarray analysis, it is helpful to have a bioinformatician involved, but the analysis can 
be done on a standard desktop computer.  
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 NGS data analysis is considerably more complex. Compared to microarray, an 
NGS experiment generates several times more data. It is also a more open-ended analysis 
than microarray analysis. There are two overarching themes of NGS analysis: assembly 
and alignment [49]. Assembly algorithms are used to reconstruct full genome sequences 
represented by the short sequencing reads NGS produces. Assembly is primarily used 
when the virus being sequenced is from an unknown sample or when no reference 
genome is available. Alignment uses a reference genome and matches the short 
sequencing reads to their proper position along the genome. This generates additional 
information compared to assembly, including the position of single nucleotide 
polymorphisms (SNPs), depth of sequencing coverage, and percentage of genome 
coverage. Depending on the size of the data files containing the sequencing reads and 
complexity of the desired analysis, it could be done on a desktop computer with 
commercially available software, or it may require a multi-core computer and a custom 
bioinformatics analysis.  
 A challenge of bioinformatics analysis of viral NGS datasets is that typically there 
is a high degree of host-derived DNA that is sequenced along with the virus, so assembly 
will mostly produce contigs matching the host genome. In addition, in the case of 
adventitious agent testing, the identity of the adventitious agent may be unknown at the 
time of sequencing, so alignments are not possible. Therefore, databases such as NCBI 
GenBank are critical to the analysis of NGS data because they can be used to suggest an 
identity for each short read. Negative selection can be done using a database of the host 
genome to remove any reads that are not viral. Positive selection can likewise be done to 
select viral reads for analysis. The resulting reduced dataset is computationally more 
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manageable. Bekkari et al. discuss the development and use of such databases in their 
analyses [50]. However, this reliance on databases means that the quality of the analysis 
is dependent on the quality of the database being used. Tom Slezak discusses some of the 
challenges with developing and maintaining a high quality public database of sequence 
data, including the capture of associated metadata and dealing with changing 
nomenclature [34]. This topic will be of continuing relevance as the rate of deposition of 
data to public databases increases [51].  
 Finding ways to query the databases discussed above very quickly is also an 
active area of research. It is not feasible to use an algorithm like the Basic Local 
Alignment Search Tool (BLAST) to find a match for each of millions of sequencing 
reads in a database the size of GenBank because the analysis would run for days [52]. 
Therefore, alternative sequence classification strategies have been developed, and they 
have been reviewed previously [53]. Most recently taxonomic classifiers based on 
classifying smaller k-mers within the sequencing reads have been developed [54, 55]. 
These classifiers run very quickly because they use a modified database to search for 
exact matches between k-mers in the individual sequencing reads and k-mers in the 
database. They then use a taxonomy tree to identify the lowest common ancestor of all k-
mers contained in each read. These sequencing read classifiers are useful to quickly 
identify which viruses may be contained in the sample, and identified reads can be 
isolated for further analysis. 
 Although the mechanics of analyzing microarray and NGS data are important, 
developing the bioinformatics expertise necessary to do these analyses is critical for 
success. Commercial analysis tools are able to help, but analyzing many samples that 
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way is not feasible. In addition, the tools available to perform NGS data analysis are 
changing rapidly, and integration of the new tools into commercial software packages can 
take years. Being able to use a basic scripting language opens up many more possibilities 
for analyzing data, as most software is released with only a command line interface. 
However, spending too much time writing a program to analyze data can take time away 
from data generation. Bioinformaticians at the FDA have developed a cloud-based 
platform to allow scientists without bioinformatics programming knowledge to analyze 
NGS data while still utilizing the latest tools. [56]. Computational power requirements 
and storage requirements are additional considerations. File transfers between 
collaborators are not a trivial issue, and currently the USDA is upgrading its network 
bandwidth to compensate for the increased need to transfer large files. Policies also need 
to be developed for the retention of sequencing data if it is to ever be reanalyzed with 
tools available in the future. 
Moving forward: the role of microarray and NGS in federal adventitious agent 
testing 
 
 Much has been accomplished in the last few years to bring microarray and NGS 
closer to the goal of routine use for adventitious agent testing, but there are still many 
unanswered questions. The first major question is related to laboratory preparation of the 
virus sample prior to sequencing or hybridization to a microarray. Regulatory 
environments require the use of standardized protocols for all samples. Many researchers 
are using different approaches to enrich for viral nucleic acid, amplify viral nucleic acid, 
and fluorescently label nucleic acid or prepare sequencing libraries. Collaboration will be 
the key to establishing a method that is most sensitive for detecting any type of viral 
nucleic acid in master seed samples. Collaboration will allow for more studies similar to 
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Modrof et al. where different protocols are tested on the same samples, as well as testing 
the same protocol in multiple laboratories to ensure repeatability across different samples 
[7]. This issue of protocol development is made more difficult by the fact that it is a 
moving target, as laboratories in academia and industry are actively working to improve 
amplification and sequencing methodologies.  
 It is important to realize that complete validation will not be possible with either 
microarray or NGS, but reliability will have to increase for either of these to serve as an 
effective screening tool. Experiments should be carefully designed and realistically 
mimic conditions in which an adventitious agent might be detected. Unfortunately, 
although cost has decreased significantly for both technologies, it is still a consideration 
in designing experiments. Regulatory officials will have to commit to support the 
implementation of microarray and NGS, including the time and expense of thoroughly 
evaluating the methods prior to their use. 
 Regulatory officials also must support the hiring and training of personnel to 
analyze the data generated by microarray and NGS. The amount of data that these 
technologies produce is unparalleled by any other laboratory technique but is 
meaningless without significant intellectual investment in the analysis.  IT infrastructure 
development is also critical, including purchasing high performance computers and 
storage to handle the terabytes of data produced. 
 The success of federal initiatives to use microarray or NGS as screening tools to 
expand the scope of adventitious agent testing is dependent on a high degree of 
collaboration within and between agencies and the biologics industry. It will involve 
laboratory staff, bioinformaticians, administrators, and IT professionals. The research 
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detailed here shows that microarray and NGS would be a beneficial addition to 
adventitious agent testing, but it is still very early in the developmental process. With a 
commitment to open communication and collaboration, it should be no problem to 
develop these technologies for adventitious agent testing in order to improve the health 
and safety of animal biologics. 
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CHAPTER 2. EVALUATION OF A VIRAL MICROARRAY AND NEXT-
GENERATION SEQUENCING FOR DETECTION OF ADVENTITIOUS AGENTS 
IN VETERINARY VACCINES 
 
A paper to be submitted to Biologicals 
Kaitlin Briena,b*, Roger Barrettec, Tod Stuberd, Joseph Hermanna, e 
Abstract 
 Vaccination is an effective strategy for preventing and reducing the severity of disease in 
animals, but vaccines contaminated with adventitious agents are a health and liability hazard. 
All manufacturers seeking licensure of vaccines for sale in the U.S. must submit their master 
seed viruses for adventitious agent testing by the Center for Veterinary Biologics to ensure 
that no biological contaminants were inadvertently introduced. Primary methods to conduct 
adventitious agent testing for viruses include cell culture conducted according to the 9 Code 
of Federal Regulations and polymerase chain reaction tests. New technologies including 
microarray and next-generation sequencing (NGS) that are capable of detecting any virus 
promise to expand the scope of adventitious agent testing. A novel viral microarray called the 
extraneous veterinary viral microarray and next-generation sequencing (NGS) were tested for 
their ability to detect a panel of licensed vaccines and a panel of mock adventitious agents 
individually and in combination. NGS was found to be a reliable approach for detection of 
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this panel of viruses, although further work is needed to increase the confidence in results 
before unknown samples are tested.  
1. Introduction 
 Several incidents, both historical and recent, of contaminants being detected in animal 
and human vaccines highlight the need for expansion of the scope of adventitious agent 
testing [1-5]. Traditional adventitious agent testing is performed according to the 9 Code of 
Federal Regulations and involves neutralizing the master seed virus and inoculating it onto a 
variety of permissive cell lines [6]. Examining cells for cytopathic effect or using various 
detection techniques determines the presence of virus. In addition, a panel of polymerase 
chain reaction (PCR) tests exists for commonly encountered contaminant viruses. However, 
cell culture detection is lengthy, labor intensive, and relies on the availability of a permissive 
cell line. PCR tests can only be performed for a selected number of agents. If a potential 
adventitious agent is not cell-culture adapted or is not targeted by a PCR, it may not be 
detected.  
  In order to address the limitations of traditional adventitious agent testing methods, 
nucleic acid detection strategies like microarray and next-generation sequencing (NGS) have 
been explored. Potential benefits and limitations of using these new technologies for 
adventitious agent testing are well documented [7-9]. These techniques are broad-spectrum, 
meaning they can simultaneously detect a multitude of viruses. No prior knowledge about the 
sample is required for testing because the viral nucleic acid is amplified using random 
primers. This random primer based approach to amplification could almost certainly expand 
the range of viruses detected, as well as decreasing the time to results. 
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 The objective of this research was to investigate whether the extraneous veterinary 
viral microarray or NGS could be used as screening tools to supplement adventitious agent 
testing at the Center for Veterinary Biologics (CVB). To accomplish this, a panel of licensed 
vaccines and a panel of positive control viruses representing adventitious agents were 
selected for testing. Positive control viruses and vaccines were tested individually and in 
combinations using both microarray and NGS.  
2. Materials and Methods 
2.1 Viruses 
 Positive control viruses were used as mock adventitious viruses (obtained from CVB and 
the National Veterinary Services Laboratories). The viruses were selected to represent 
diverse virus families and common contaminants of biologicals. The mock adventitious 
viruses included bovine viral diarrhea virus-1 (BVDV), rabies virus (RABV), reovirus 
(REO), avian leukosis virus (ALV), chicken anemia virus (CAV), and Marek’s disease virus 
(MDV) (Table 1). Vaccines were selected to represent diverse virus families. The vaccines 
selected were porcine respiratory and reproductive syndrome virus (PRRSV), porcine 
circovirus-2 (PCV), pseudorabies virus (PRV), infectious bronchitis virus (IBV), infectious 
bursal disease (IBD) virus, hemorrhagic enteritis virus (HEV), and fowlpox virus (FPV) 
(Table 2). Vaccines selected comprised live, modified live, and killed vaccines. Vaccines 
were hydrated using included diluent or 25 mL of water if no diluent was included. 
2.2 Virus enrichment and nucleic acid extraction 
Virus enrichment was performed to reduce the amount of host DNA in the viral 
samples and was done according to the protocol presented in Erlandsson, et al [10]. Briefly, 
viruses were mixed at a 1:1 ratio by volume (if applicable). A volume of 800-1000 μl of virus 
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was centrifuged for ten minutes at 14,000 RCF. Samples were then filtered through a 0.45 
μm or 0.22 μm spin filter (Corning Costar Spin-X sterile cellulose acetate filter) for two 
minutes at 1,400 RCF. Six μl each of DNase I reaction buffer and DNase I (Invitrogen) were 
added to 400 μl of filtered sample and shaken at 300 rpm at room temperature for ninety 
minutes. Six μl of 25 mM ethylenediaminetetraacetic acid (EDTA) was added, and enzyme 
was inactivated at 65° C for ten minutes. Subsequently, total nucleic acid was extracted from 
400 μl of treated sample using the Purelink Viral RNA/DNA Mini Kit (Invitrogen) according 
to manufacturer’s instructions.  
2.3 Multiple displacement amplification 
Viral RNA/DNA was amplified from total nucleic acid using the Qiagen REPLI-g 
Cell WGA and WTA Kit. Briefly, samples were divided, and the RNA fraction underwent a 
DNA digestion followed by reverse transcription, ligation of cDNA fragments, and 
amplification using oligo(dT) primer, random primers, and Phi29 polymerase. The DNA 
fraction is modified for high efficiency ligation, followed by the ligation and amplification 
reactions used in the RNA fraction (Figure 1).  After amplification, DNA was purified using 
the Qiagen QIAamp DNA Mini Kit with a modified protocol for purification of REPLI-g 
amplified DNA.  
2.4 Novel microarray design- the extraneous veterinary viral microarray 
Microarray design for specific viral agents was performed using an oligonucleotide 
selection algorithm based on a previous approach by Barrette et al [11]. The microarray 
feature selection algorithm was scripted in Python (v2.7) with database management through 
MySQL (v5.6). Variations of the originally described method included targeting a limited 
subset of the NCBI nucleotide database to include common viral adventitious agents of 
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interest. Briefly, full genome sequences were obtained from the NCBI nucleotide database 
for all target viruses of interest. Viral genome sequences were ‘fragmented’ into overlapping 
60 nucleotide sequences to provide the initial candidate library. Candidate oligonucleotide 
sequences were filtered to remove redundancy, and compared using the tblastx algorithm of 
the Basic Local Alignment Search Tool (BLAST) to other related viral genomes within the 
NCBI nucleotide database to target coding regions for taxonomically conserved viral 
peptides [12]. Sequences identified by tblastx as unique, but similar (>90% identity at the 
nucleotide level) were included as unique microarray features in the final array design. This 
pipeline identified 109,795 oligonucleotides, which were submitted to Agilent using E-array 
software (Agilent Technologies), for synthesis on a custom 4 x 180K oligonucleotide array. 
2.5 Microarray 
Amplified DNA was fluorescently labeled using the Invitrogen BioPrime Array CGH 
Genomic Labeling System with Alexa-Fluor 555-aha-dUTP or Alexa-Fluor 647-aha-dUTP 
(Molecular Probes) according to manufacturer’s instructions. Unbound fluors were removed 
with the included purification module. The Agilent Oligo aCGH/ChIP-on-Chip Hybridization 
Kit was used to prepare the hybridization solution. Fifty-five μl of blocking agent, 275 μl of 
hybridization buffer, 25 μl of salmon sperm DNA (Invitrogen), and 39 μl of labeled DNA 
were mixed and hybridized on the slide at 67° C for 4-16 hours. The slide was washed with 
the Agilent Oligo aCGH/ChIP-on-chip Wash Buffer Kit, and data was collected using 
Molecular Devices GenePix 4400 scanner with Genepix Pro 7 software. 
 Analysis was performed using a Microsoft Access database using a modified Genepix 
Array List (.gal) file which included fluorescence intensity and taxonomic information, 
including species and genus taxonomy IDs, for each microarray locus. Microarray loci with 
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mean fluorescence intensity greater than 3.5 standard deviations over the mean across all loci 
were considered ‘positive’ for this analysis. Finally, the percentage of positive features with a 
given species level NCBI taxonomy ID number were reported.  
2.6 Next-generation sequencing  
Amplified DNA was prepared for sequencing using the Nextera XT library 
preparation kit (Illumina) according to manufacturer’s instructions. Sequencing was 
performed using the Illumina MiSeq instrument with v2 reagents at the National Veterinary 
Services Laboratory (Ames, IA). 
Raw fastq files from the sequencer were analyzed using Kraken software (v0.10.5-
beta) using the standard database (all RefSeq bacterial and viral sequences) to sort reads into 
phylogenetic groups (Figure 2) [13]. Reads that were classified to an NCBI taxonomy 
identification that contained the word “virus” were selected for further analysis. Selected 
taxonomies that included the words “unclassified”, “DNA”, “RNA”, “transcribing”, “pea”, 
“invertebrate”, “molluscum”, “moorhen”, “T4”, “T5”, “T7”, “like”, “cryptic”, “globosa”, 
“occidentalis”, “viridae”, “mosaic”, “mottle”, “human”, “baculo” and “ichno” were excluded 
from further analysis. These groups were excluded either because they signified the broadest 
levels of the phylogenetic tree and were not useful for selecting a specific genome to analyze 
further, or they signified bacteriophages, insect viruses, plant viruses, or human viruses that 
were not relevant to this analysis. Clusters reflecting phylogenetic relationships of selected 
taxonomy ID numbers were generated (e.g. a genus level cluster included reads assigned by 
Kraken to that genus taxonomy ID and reads identified more specifically to its species and 
subspecies taxonomies). Reads in each cluster were assembled using ABySS (v1.5.2), and 
the resulting contigs were compared individually to previously sequenced viruses in the 
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NCBI nucleotide database using the blastn algorithm of the Basic Local Alignment Search 
Tool (BLAST) with default parameters [12, 14]. The genome that was identified as the top 
result by BLAST for the most contigs that also contained the word “genome” (most often 
used in the phrase “complete genome”) was then used as a reference genome to do an 
alignment using the full fastq file and the Burrows-Wheeler Aligner (v0.7.10, bwa-mem 
algorithm with a mismatch penalty of one) [15]. In the case of segmented genomes, all 
genomic segments were concatenated and treated as one reference genome. The number of 
aligned reads, percent of total reads that aligned, percent genome coverage, and average 
depth of sequencing were reported from this reference alignment. Accession numbers are 
reported in the results. 
3. Results 
 
3.1 Mock contaminants and vaccines tested individually 
 Positive control viruses were selected to act as mock contaminants (Table 1), and 
several licensed vaccines were selected (Table 2) for the experiment. The viruses were 
chosen with consideration given to representing diverse virus families. Nucleic acid from 
each mock contaminant or vaccine was extracted individually, amplified with multiple 
displacement amplification, and tested in tandem using the microarray and Illumina 
sequencing (Figure 1). Mock contaminants had between 4-100% positive microarray loci for 
the expected virus species (Table 3). Between 8-69% percent of total sequencing reads were 
identified as belonging to the respective mock contaminants (Table 3). Genome coverage for 
the mock contaminants ranged between 92-98%. Vaccines had between 30-99% positive 
microarray loci for the expected virus species (Table 4). Between 0.5-85% of total 
sequencing reads were identified as belonging to the respective vaccine virus. Genome 
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coverage for the vaccine ranged between 73-98%, although all vaccines but the Pseudorabies 
virus vaccine had at least 94% genome coverage.  
3.2 Mock contaminated vaccine trials 
 Mock contaminants and vaccines were divided into mammalian and avian categories. 
A mock contaminant and a vaccine from the same category were mixed together 1:1 by 
volume prior to virus enrichment and nucleic acid extraction. The amplification procedure 
was followed as for individual viruses above (Figure 1). The three reovirus combination 
samples were not tested with the microarray because of the very low hybridization 
percentage of the individual Reovirus microarray. 
 It was determined based on the results of the individual virus trials that 30% positive 
microarray loci for the expected virus species would be required to consider a microarray 
trial successful. Using this cutoff, half of the avian trials and 1/6 of the mammalian trials 
using the microarray were able to detect both viruses (Table 5 and 6).  
 Genome coverage is an informative metric because it allows some indication of the 
quality of sequencing results and whether the entire virus genome is present or only a portion 
of it. Near-full genome coverage was required to determine successful detection of viruses by 
NGS because the experimental goal was to recover the full genome of the known viruses 
spiked into the sample. Based on the individual virus sequencing results, where the lowest 
percent genome coverage was 73%, 80% genome coverage for each virus was considered 
successful. Greater than 80% genome coverage was obtained for both viruses in 6/10 avian 
trials and 6/9 mammalian trials (Table 5 and 6). In the avian trials, 2/3 IBD contaminants had 
less than 15% genome coverage (Table 5). The two avian double-stranded DNA virus 
vaccines spiked with MDV did not meet the 80% genome coverage threshold for both viruses 
 29 
(Table 5). The three mammalian trials containing PRV failed because they had low coverage 
of the PRV genome. This is not surprising because greater than 80% genome coverage was 
never obtained for PRV (Table 4). At least 92% genome coverage was generated for the 
mock contaminant in all mammalian trials. 
4. Discussion 
4.1 General conclusions 
 Using the amplification method outlined in Figure 1, both the extraneous veterinary 
viral microarray and NGS were able to detect all individual positive control and vaccine 
viruses, with the exception that the microarray failed to detect Porcine Reovirus and NGS 
failed to detect Pseudorabies virus. When the viruses were combined, the detection rate was 
considerably lower. Both viruses were detected in half to two-thirds of samples tested by 
sequencing and in a sixth to half of the samples tested by microarray. However, these 
conclusions are limited as it is difficult to determine an appropriate threshold for determining 
presence or absence of a given virus without a larger set of samples, including biological and 
technical replicates.        
 Generally speaking, it is more possible to draw conclusions based on the NGS data. 
The microarray is less able than NGS to make a distinction between true virus presence and 
non-specific binding of background nucleic acid. This microarray was designed with a select 
number of viruses represented in the hope of maximizing the sensitivity of virus detection. 
However, the large number of loci per virus resulted in a less stringent selection of 
oligonucleotide sequences, which may have increased the amount of non-specific binding. It 
is possible that an improved analysis algorithm to predict cross-species binding for the 
microarray would give more confidence in differentiating non-specific binding from true 
 30 
virus presence. In contrast, the specificity of NGS results makes even very low percent 
genome coverage indicative of viral presence. NGS was able to make correct strain level 
assignments in several cases (data not shown). Background nucleic acid is less of a problem 
for NGS because it is either specifically identified or discarded in the NGS analysis. If 
further analysis is needed to examine the specific sequence of the virus present for some 
reason, existing data may be revisited. For these reasons, further efforts will be focused on 
developing a reliable method for virus detection by NGS. 
4.2 Strengths and limitations of this study 
 Several recent studies have been published on the topic of using microarrays and/or 
NGS for the purpose of detecting adventitious agents [8, 16-20]. These studies have been 
very informative but have typically tested a very limited number of samples in favor of doing 
a titration to determine sensitivity. This information is critical, but it was determined that 
before those types of studies could be performed at CVB, we needed to determine the 
feasibility of using these technologies with a broader set of viruses. Rather than titrating 
single viruses, we tested the viruses primarily in combinations, mimicking the scenario in 
which adventitious agents are detected. Overall, the method used seems to have been 
successful. A few real adventitious agents were detected, including porcine circovirus 1 in a 
CVB positive control, Marek’s disease virus in a CVB positive control, and endogenous 
retroviruses in several samples (data not shown).  
 Although our study used a wide variety of samples, there are several disadvantages of 
this approach. Using well-characterized samples with genome copy information determined 
by qPCR is the strategy implemented by most recent publications. We determined that it was 
not feasible to use qPCR for this number of viruses because CVB had no preexisting qPCRs 
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developed for these agents, nor reference standards with which to compare experimental 
samples. Infectivity concentrations were not compared because this information was not 
available for all samples, and the methods used to determine infectivity are not comparable 
across all samples (e.g. ELISA relative potency vs TCID50). Our choice of samples reflected 
the most realistic mock contaminants and allowed us to test a wide variety of samples 
without regard to the availability of control data. However, not having control data makes it 
more difficult to draw conclusions about failed samples.  
 It was initially hypothesized that difference in genome type (DNA vs. RNA, double-
stranded vs. single stranded, etc.) would influence amplification and therefore likelihood of 
detection. We encountered several combinations of viruses with different genome types in 
which both viruses were not detected at the 80% genome coverage threshold. Without 
rigorous genome concentration data and an even larger pool of virus samples, we are unable 
to determine if the failure of detection was caused by a virus specific problem, too large of a 
difference in concentration between viruses, or the difficulty in amplifying different genome 
types with one method.  
 The amplification method includes a ligation step prior to amplification with phi29 
polymerase. During method development, the only goal of the study was to determine 
presence or absence of viruses. However, in some situations, the difference between the 
vaccine virus and an adventitious agent is as small as a few hundred base pair insertion of 
host DNA, as in the case of cytopathic and noncytopathic BVD viruses [21]. In this case, it is 
difficult for the data generated by this ligation-mediated amplification to be used for further 
analysis. Any host DNA in the sample could conceivably be ligated to the virus DNA in the 
same position as the expected insertion. In addition, contigs generated by ligation-amplified 
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DNA could be misleading. The DNA strand that is amplified is likely composed of DNA 
from multiple sources that had been ligated together. When it is broken in order to sequence, 
and contigs are assembled after sequencing (by matching overlapping ends of the sequencing 
reads), the resulting contigs may or may not be an accurate reflection of a single virus 
genome. A good reference genome would be needed to ensure that contigs are able to align 
to the genome appropriately. When in-depth analysis of the sequence data is required, it may 
be necessary to perform a virus specific amplification to obtain higher quality data. However, 
for assessing viral presence/absence, it was determined based on a limited number of samples 
that this method was the most robust (data not shown). 
4.3 Remaining questions and future directions 
 Further investigation is certainly needed in a variety of areas. The first area is in 
method development. Using this random priming amplification method results in background 
nucleic acid from host being amplified along with the vaccine virus, potentially decreasing 
the likelihood of detecting adventitious agents. In general, 20-99% of NGS reads are non-
viral. The low percent genome coverage of some virus combinations in our study indicates 
that more work is needed to develop a robust amplification method. In addition, viral 
enrichment procedures will need to be studied further. Some viruses, like fowlpox virus, are 
very large (0.3 μM), and detection was inhibited when virus was filtered through a 0.22 μM 
filter prior to nucleic acid extraction (data not shown). However, it’s possible that using a .45 
μM filter or no filtration would result in a higher degree of background nucleic acid that 
could inhibit virus detection. The best method for performing nuclease treatment prior to 
nucleic acid extraction will also need to be examined. Preliminary data suggests it is helpful 
to obtain a higher number of viral sequencing reads, but it was not studied extensively. 
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 Another area needing further investigation is conducting comparisons of NGS for 
virus detection with traditional, validated methods. Performing titrations of several 
representative viruses in combination with other viruses will help to determine the relative 
sensitivities of NGS and traditional methods. One of the challenges of broad-spectrum 
detection methods is that there is no way to validate the method. It is not feasible to test all 
viruses, never mind all combinations of viruses, due to cost and time. However, additional 
studies should provide information about the risks and benefits of including NGS as a 
screening tool for adventitious agent testing.  
 The third area of concern is related to analysis of the sequencing data. One of the 
challenges of this project was to determine criteria to classify a successful test and an 
unsuccessful test. Whether the number of aligned reads (and percent of total reads) is an 
important metric to consider, or whether percent genome coverage is the more important 
indicator of presence of virus should be investigated. The percent genome coverage cutoff of 
80% was chosen based on the sequencing results for single viruses. More work is needed to 
determine an appropriate percent coverage cutoff when an adventitious agent contaminates a 
vaccine at a very low concentration.  
 Detection of nucleic acid does not necessarily mean that infectious viral particles are 
present. Therefore, much time could be wasted on investigating nonreplicative adventitious 
viruses that would not have been detected using traditional methods. Regulatory officials will 
need to establish parameters for additional testing and determine where NGS fits into the 
adventitious agent testing landscape.  
 This preliminary study on the feasibility of using microarray and NGS at CVB for the 
purpose of detecting adventitious agents in vaccine master seeds presents evidence that NGS 
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is especially worthy of additional investigation. All mock contaminant viruses were detected 
at some level in combination with a vaccine, although several did not meet the 80% genome 
coverage threshold. In addition, NGS is capable of providing more information than the 
microarray about any viruses found. Once a robust amplification method is determined, all 
routine samples that are tested in CVB should be tested with the NGS protocol in order to 
start building a larger pool of data to make regulatory decisions about the future of NGS for 
adventitious agent testing. It may be difficult to reach the level of confidence required to rule 
a sample negative for virus by NGS alone, but NGS can supplement traditional testing. NGS 
platforms continue to   improve library preparation protocols and increase their depth of 
sequencing, which should aid in the detection of low concentration viruses. Research is 
ongoing on how NGS can be used by the Center for Veterinary Biologics to improve the 
safety of veterinary biologics.  
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Table 1. Mock contaminants selected represent diverse viral families and genome types. 
 
 
Virus family Virus Abbreviation Genome 
Type  
Genome 
Size 
Retroviridae Avian leukosis virus ALV ssRNA (rt) 7.5 kb 
Circoviridae Chicken anemia virus CAV ssDNA 2.3 kb 
Herpesviridae Marek’s disease virus MDV dsDNA 166 kb 
Flaviviridae Bovine viral diarrhea virus BVDV ssRNA (+) 12.6 kb 
Rhabdoviridae Rabies virus RABV ssRNA (-) 11.9 kb 
Reoviridae Porcine reovirus REO dsRNA 20 kb 
(segmented) 
 
 
 
Table 2. Vaccines selected represent diverse viral families and genome types.  
 
 
Virus family Virus Abbreviation Genome 
Type  
Genome 
Size 
Coronaviridae Infectious bronchitis virus IBV ssRNA (+) 27.5 kb 
Birnaviridae Infectious bursal disease virus IBD dsRNA 5.9 kb 
(segmented) 
Adenoviridae Hemorrhagic enteritis  virus HEV dsDNA 26.3 kb 
Poxviridae Fowlpox virus FPV dsDNA 288.5 kb 
Circoviridae Porcine circovirus PCV ssDNA 1.8 kb 
Herpesviridae Pseudorabies PRV dsDNA 143.4 kb 
Arteriviridae Porcine reproductive and 
respiratory syndrome virus 
PRRSV ssRNA (+) 15.4 kb 
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Reaction to amplify 
RNA viruses 
Reaction to amplify 
DNA viruses 
Illumina MiSeq 
Virus enrichment 
and nucleic acid 
extraction 
DNA prep. reaction 
and amplification 
Reverse transcription 
and amplification 
DNA and RNA 
reactions pooled 
Fluorescent labeling Nextera XT library prep 
Microarray 
Figure 1. Sample preparation workflow followed to amplify viral RNA/DNA 
prior to microarray or sequencing. 
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Classify individual reads 
with Kraken 
Recover reads belonging to 
viral taxa 
De novo assembly with 
ABySS 
Identify resulting contigs 
using BLAST and nt 
database 
Align using BWA to the 
genome that had the most 
matching contigs  
Output a text report 
Figure 2. NGS data analysis workflow followed starting with raw FASTQ files from the 
sequencing instrument. 
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Table 3. Mock contaminants tested independently by microarray and sequencing. 
 
  
Sample Species Percentage 
of Positive 
Microarray Loci  
Number of NGS Reads  
(% of total) 
Percent 
Genome 
Coverage  
NCBI Accession 
number 
ALV 98 504,284 (23% total) 97.7  KF866225 
CAV 100 
 
161,626 (8% total) 98.5  DQ991394 
MDV 35 209,826 (11% total) 95.2  HQ840738 
BVDV 75 957,622 (43% total) 98.6  M31182 
RABV 72 527,502 (21% total) 98.5  JQ944709 
REO 4 787,590 (69% total) 92.3  JX415465-
JX415474 
 
  
Abbreviations: ALV (avian leukosis virus), CAV (chicken anemia virus), MDV (Marek’s 
disease virus), BVDV (bovine viral diarrhea virus), RABV (rabies virus), REO (porcine 
reovirus) 
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Table 4. Licensed vaccines tested independently by microarray and sequencing. 
 
 
Sample Species Percentage 
of Positive 
Microarray Loci 
Number of NGS Reads 
(% of total) 
Percent 
Genome 
Coverage  
NCBI 
Accession 
number 
IBV 63 1,514,952 (62% total) 98.6  KJ435286 
IBD 53 13,298 (0.5% total) 98.4  NC_004178-
NC_004179 
HEV 99 1,245,860 (85% total) 98.6  AF074946 
FPV 30 520,740 (25% total) 94.9 AF198100 
PCV 39 75,698 (6% total) 96.8 KJ128274 
PRV 31 25,354 (2% total) 73.2 KJ717942 
PRRSV 82 337,246 (19% total) 98.6 KF771273 
 
  
Abbreviations: IBV (infectious bronchitis virus), IBD (infectious bursal disease virus), HEV 
(hemorrhagic enteritis virus), FPV (fowlpox virus), PCV (porcine circovirus), PRV 
(pseudorabies virus), PRRSV (porcine reproductive and respiratory syndrome virus) 
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Table 5. Avian mock contaminant and vaccine combinations tested by microarray and 
sequencing. 
 
 
Mock 
Contaminant 
(MC) 
Vaccine (V) Species 
Percentage 
of Positive 
Microarray 
Loci 
Number of NGS Reads  
(% of total) 
Percent 
Genome 
Coverage 
ALV IBV MC: 78 
V:    47 
MC: 64,706 (4%) 
V:    567,518 (33%) 
MC: 97.4  
V:    98.6 
IBD MC: 0 
V:    55 
MC: 250 (0.01%) 
V:    5,176 (0.3%) 
MC: 89.6 
V:    98.4 
HEV MC: 30 
V:    83 
MC: 3,738 (0.7%) 
V:    80,078 (14%) 
MC: 94.3 
V:    98.4 
CAV IBV MC: 97 
V:    30 
MC: 115,386 (7%) 
V:    463,568 (28%) 
MC: 98.5 
V:    98.6 
IBD MC: 0 
V:    3 
MC: 2 (0.00%) 
V:    586 (0.04%) 
MC: 14.4 
V:    95.6 
HEV MC: 100 
V:    97 
MC: 59,438 (2%) 
V:    184,362 (5%) 
MC: 98.5 
V:    98.6 
MDV IBV MC: 52 
V:    78 
MC: 125,008 (5%) 
V:    1,001,312 (40%) 
MC: 88.9 
V:    98.6 
IBD MC: 0.03 
V:    25 
MC: 380 (0.04%) 
V:    3,288 (0.3%) 
MC: 10.7 
V:    98.4 
HEV MC: 1 
V:    34 
MC: 3,684 (0.5%) 
V:    33,588 (4%) 
MC: 63.0 
V:    98.3 
FPV MC: 35 
V:    0.5 
MC: 104,072 (9%) 
V:    14,304 (1%) 
MC: 94.2 
V:    53.1 
 
 
  
Abbreviations: ALV (avian leukosis virus), CAV (chicken anemia virus), MDV (Marek’s 
disease virus), IBV (infectious bronchitis virus), IBD (infectious bursal disease virus), HEV 
(hemorrhagic enteritis virus), FPV (fowlpox virus) 
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Table 6. Mammalian mock-contaminant and vaccine combinations tested by 
microarray and sequencing. 
 
 
Mock Contaminant 
(MC) 
Vaccine 
(V) 
Species 
Percentage 
of Positive 
Microarray 
Loci 
Number of NGS Reads 
(% of total) 
Percent 
Genome 
Coverage 
BVDV PCV MC: 66 
V:    21 
MC: 543,866 (31%) 
V:    12,366 (0.7%) 
MC: 93.7 
V:    98.5 
PRV MC: 39 
V:    6 
MC: 51,174 (3%) 
V:    11,534 (0.7%) 
MC: 93.7 
V:    52.2 
PRRSV  MC: 57 
V:    68 
MC: 172,478 (17%) 
V:    46,078 (5%) 
MC: 98.6 
V:    98.6 
REO PCV N/A MC: 474,270 (31%) 
V:    49,540 (3%) 
MC: 92.4 
V:    95.4 
PRV N/A MC: 660,866 (44%) 
V:    101,750 (7%) 
MC: 92.4 
V:    70.0 
PRRSV N/A MC: 1,118,320 (54%) 
V:    386,108 (19%) 
MC: 92.3 
V:    98.6 
RABV  PCV MC: 53 
V:    0 
MC: 50,390 (3%) 
V:    1,102 (0.07%) 
MC: 98.0 
V:    81.0 
PRV MC: 74 
V:    4 
MC: 142,032 (12%) 
V:    6,944 (0.6%) 
MC: 98.5 
V:    34.4 
PRRSV  MC: 60 
V:    16 
MC: 90,086 (6%) 
V:    11,050 (0.8%) 
MC: 98.5 
V:    98.6 
 
 
Abbreviations: BVDV (bovine viral diarrhea virus), REO (porcine reovirus), RABV (rabies 
virus), PCV (porcine circovirus), PRV (pseudorabies virus), PRRSV (porcine reproductive and 
respiratory syndrome virus) 
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CHAPTER 3. EVALUATION OF A VIRAL MICROARRAY AND NEXT- 
GENERATION SEQUENCING FOR DETECTION OF BOVINE VIRAL 
DIARRHEA VIRUSES 
 
Abstract 
 Bovine viral diarrhea viruses are common contaminants in vaccines, as most 
viruses are grown in cell culture with the use of fetal bovine serum. Two major genotypes 
are present in North America, type 1 and type 2. A novel viral microarray, the extraneous 
veterinary viral microarray, and next-generation sequencing (NGS) were previously 
tested for their ability to detect combinations of unrelated viruses. This study investigated 
the ability of the microarray and NGS to detect and distinguish between related viruses. 
Both the microarray and NGS were able to distinguish the two genotypes when presented 
individually, and NGS was able to give strain level identification. Both the microarray 
and NGS were also able to detect both genotypes when they were tested in combination. 
Determining the presence of multiple strains of the same virus genotype requires further 
investigation. 
1. Introduction 
 Bovine viral diarrhea (BVD) viruses have a single stranded RNA genome and 
belong to the Flaviviridae family in the Pestivirus genus [1]. BVD viruses are a 
genetically and antigenically diverse group, and they infect ruminants primarily [1]. Two 
biotypes of the virus exist, cytopathic virus, which causes cell lysis when grown in cell 
culture, and noncytopathic virus, which does not [2]. Persistently infected cows are born 
when they are exposed to noncytopathic BVDV in the first 120 days of gestation, and a 
recombination event generating a cytopathic strain of the virus can trigger fatal mucosal 
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disease [3, 4]. The prevalence of persistently infected animals is estimated to be between 
0.5-2%, but 60-85% of cattle have antibody for BVDV, showing past exposure [5]. 
 The high prevalence of BVDV in cattle populations means that it is a very 
common contaminant found in fetal bovine serum (FBS). FBS is used as a nutrient source 
to support growth of cell culture and virus during vaccine production. If contaminated 
FBS is used during vaccine production, the final product may also be contaminated with 
BVDV. All mammalian master seed viruses are tested for BVDV for this reason. One 
study tested one thousand lots of FBS for BVDV and found 203 lots were contaminated 
[6]. More recently, atypical (non-type 1 or type 2) BVD viruses have been isolated from 
FBS [7-9]. The conventional PCR tests used to detect BVD viruses may be unsuited to 
detect these atypical viruses because mismatches in primer binding regions can inhibit 
amplification [7].  
 Microarray and next-generation sequencing (NGS) can be used in conjunction 
with random primer amplification to supplement other methods for BVDV detection. 
This random primer amplification method is well suited for detecting emerging BVD 
viruses because virus can be amplified without prior knowledge of the sequence. In 
addition, NGS can provide a specific identification if the genome sequence is available in 
a public database. The purpose of this research was to determine if a novel viral 
microarray and NGS could be used to detect both BVDV-1 and BVDV-2. The viruses 
were examined individually to determine the ability of the microarray and NGS to 
distinguish between genotypes. In addition, the viruses were combined to test the ability 
of the microarray and NGS to determine the presence of multiple viruses. 
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2. Materials and Methods 
2.1 Viruses 
 BVDV-1 strain NADL, BVDV-1 strain Singer, and BVDV-2 strain 125c were 
obtained from CVB stocks. Complete genome sequences for type 1 BVD viruses were 
available publically from NCBI GenBank (NADL: accession M31182.1, Singer: 
accession DQ088995.2). A complete genome sequence for BVDV-2 strain 125c was 
made available by Dr. John Neill, Agricultural Research Service. 
2.2 Virus amplification, microarray, and NGS  
 Materials and methods were the same as presented in chapter 2.   
2.3 Data analysis 
 Analysis of microarray data was done according to the method presented in 
chapter 2. The NGS data analysis workflow presented in chapter 2 was done, with 
additional alignments generated to include the other BVDV strains detailed in section 2.1. 
3. Results 
3.1 BVDV-1 and BVDV-2 tested individually 
 Both BVDV-1 NADL and BVDV-2 were tested individually to determine relative 
cross-detection using the microarray and NGS (Table 7). The microarray had a higher 
percentage of true positive loci for the expected viruses than false positive loci for the 
absent viruses, with a difference of at least 58%. Both trials had false positive loci 
percentages less than the 30% cutoff discussed in chapter 2 for the absent viruses. NGS 
data showed that there were at least 75% fewer reads that aligned to the genome sequence 
of the absent virus, and at least thirteen percentage points lower genome coverage. 
However, the BVDV-2 virus sample had greater than 80% genome coverage for BVDV-
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1, suggesting presence of BVDV-1 according to the criteria established in chapter 2. The 
relatively high number of BVDV-1 reads in the BVDV-2 sample may be attributed to 
barcode cross-talk from the sequencer, as BVDV-1 isolates were run on the sequencer at 
the same time [10]. This is supported by the presence of 62,036 reads that aligned to the 
BVDV-2 virus genome (covering 89.4% of the genome) in the sample with both strains 
of BVDV-1 virus. The BVDV-1 NADL only sample presented here was sequenced 
separately with unrelated viruses, and the percent genome coverage for BVDV-2 is below 
the percent identity shared between BVDV-1 and BVDV-2.  
3.2 BVDV-1 and BVDV-2 tested in combination 
 BVDV-1 NADL and BVDV-2 were combined 1:1 by volume prior to extraction 
and amplified according to the procedure in Figure 1. The results show that both BVDV-
1 and BVDV-2 could be detected (Table 8). The microarray had a high percentage of 
positive loci for both viruses: 72% of BVDV-1 loci were positive and 86% for BVDV-2 
loci were positive. This is in contrast to the results when only one virus was present, 
where the absent virus had a percentage of positive loci below the 30% threshold. The 
NGS results for this sample showed that there were approximately 400,000 reads that 
aligned to each virus genome, and greater than 97% genome coverage for each virus. 
This is suggestive of the presence of both viruses, as an alignment between the genome 
sequences of BVDV-2 125c and BVDV-1 NADL using the megablast algorithm of the 
Basic Local Alignment Search Tool showed a 73% identity between the two viruses [11].  
3.3 Two strains of BVDV-1 tested in combination 
 Two historically distinct strains of BVDV-1, BVDV-1 strain NADL and BVDV-1 
strain Singer, were tested as above (Table 9). The results of this test are more difficult to 
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interpret, as the microarray was not designed to give strain level distinction. Seventy-one 
percent of BVDV-1 species-specific loci were positive, but 100% of BVDV-1 NADL 
strain-specific loci were positive. BVDV-1 Singer was not used as a reference genome to 
design the array, so strain specific data was not available. The NGS data showed that 
each strain had at least 473,000 aligned reads and greater than 98.4% genome coverage. 
However, the standard analysis detailed in Figure 2 failed to detect BVDV-1 NADL, as 
more contigs were assembled matching BVDV-1 Singer and only the top result is chosen 
for alignment. An alignment of the two sequences using megablast showed the two 
strains share a 96% identity, so it is difficult to determine if the high level of genome 
coverage observed is caused by the presence of both viruses or the fact that many reads 
align to both genomes. 
4. Discussion 
 Both the microarray and NGS were able to distinguish between BVDV-1 and 
BVDV-2 viruses when they were tested individually, as evidenced by the higher 
percentage of positive microarray loci and higher percentage of genome coverage for the 
present virus than the absent virus. Both technologies were also able to detect BVDV-1 
and BVDV-2 in combination, as both viruses had high percentages of positive microarray 
loci and high percentages of genome coverage. However, in the case of two strains of 
BVDV-1 tested in combination, the microarray was not able to detect both strains, as one 
of the strains was not used in the design process for the array. NGS data showed a high 
percentage of genome coverage for both strains, which in this case indicates the presence 
of both viruses. However, it was known in advance which virus strains were present, so a 
targeted approach could be used to generate genome alignments.  
 49 
 Alignment may not be the best tool to determine absence of a related virus, as 
many reads from the present virus will also align to the related genome. This is especially 
relevant in the case highlighted here of attempting to detect multiple strains of BVDV-1 
virus in one sample. They share a very high percent identity (96%), so the same NGS 
reads will likely align to both genomes. In the case of an unknown sample, it would be 
very difficult to determine whether multiple viruses were present without targeting 
specific conserved loci that distinguish the viruses. This is the approach used by most 
BVDV PCRs, which target the conserved 5’ un-translated region to distinguish BVDV-1 
from BVDV-2 [12, 13] 
 Further work will be needed to determine if other related viruses tested 
individually can be distinguished by microarray and NGS. Determining the presence of 
multiple viruses in a sample will require further investigation into specific phylogenies of 
the viruses of interest to determine conserved regions that are diagnostic of viral 
presence. This task is only suited to NGS data because the microarray may not contain 
oligonucleotides matching those conserved regions. NGS is also the platform most 
capable of detecting atypical BVD viruses because new BVDV sequences can be 
integrated into analyses as they are added to public databases. The NGS data analysis 
protocol currently in use seems to be most useful for identifying the presence of unrelated 
viruses. Detecting BVD viruses in master seed viruses is of high importance, and 
research is ongoing to determine how to best utilize NGS for this purpose. 
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Table 7. Cross-detection of bovine viral diarrhea virus 1 (BVDV-1) and bovine viral 
diarrhea virus 2 (BVDV-2) in samples in which only one virus is present. 
 
 
Sample Species Percent 
Positive 
Microarray Loci 
Number of NGS 
Reads Identified by 
Kraken 
Number of Aligned 
NGS Reads 
Percent Genome 
Coverage 
BVDV-1  BVDV-1: 75 
BVDV-2: 17 
BVDV-1: 953,634 
BVDV-2: 2 
BVDV-1: 957,622 
BVDV-2: 130,046 
BVDV-1: 98.6 
BVDV-2: 63.3 
BVDV-2 BVDV-2: 89 
BVDV-1: 21 
BVDV-2: 843,360 
BVDV-1: 50,972 
BVDV-2: 1,053,050 
BVDV-1: 263,494 
BVDV-2: 97.5 
BVDV-1: 84.8 
 
 
 
Table 8. Detection of BVDV-1 and BVDV-2 viruses in a sample in which both 
viruses are present. 
 
 
Virus 1 Virus 2 Species Percentage of 
Positive Microarray Loci 
Number of 
Aligned NGS 
Reads 
Percent Genome 
Coverage 
BVDV-1 
strain NADL 
BVDV-2 
strain 125 
BVDV-1: 72 
BVDV-2: 86 
BVDV-1: 441,850  
BVDV-2: 399,394 
 
BVDV-1: 98.6 
BVDV-2: 97.5 
 
 
Table 9.  Detection of two strains of BVDV-1 in a sample in which both strains are 
present. 
 
 
Virus 1 Virus 2 Species Percentage of 
Positive Microarray Loci 
Number of 
Aligned NGS 
Reads 
Percent 
Genome 
Coverage 
BVDV-1 strain 
NADL 
BVDV-1a strain 
Singer 
BVDV-1 (all): 71 
NADL: 100 
 
NADL: 473,410 
Singer: 473,896 
NADL: 98.6 
Singer: 98.5 
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CHAPTER 4. GENERAL CONCLUSIONS 
 
 The research presented in this thesis shows that the extraneous veterinary viral 
microarray presented here and NGS are tools worthy of further investigation for 
adventitious agent testing. NGS is especially useful because it is possible to capitalize on 
the increasing volume of DNA sequences being added to public databases. For this 
reason, it is more feasible to detect novel and emerging viruses using NGS. Incorporating 
novel and emerging viruses would likely require a redesign of the microarray. NGS also 
has the ability to identify contaminants with strain level specificity. 
 Nucleic acid from mock contaminant and vaccine mixtures was detected in all 
samples, although several did not meet the high percentage of positive microarray loci or 
high percentage of genome coverage criteria. Additional investigation is needed to 
determine an appropriate threshold for detection. BVDV-1 and BVDV-2 could also be 
distinguished by both microarray and NGS.   
 Further development is needed in sample preparation and data analysis. The 
Center for Veterinary Biologics is committed to embracing new technologies in order to 
increase the safety of veterinary biologics, so additional work on implementing NGS as a 
screening tool will be conducted. 
 
